CNTX Stock — Context Therapeutics Inc.: Cash, EV, Pipeline

Share price

$0.37

Market cap

$33.8M

Cash

$43.0M

Enterprise value

-$9.2M

Balance sheet

Cash	$43.0M
Debt	$0.0M
Net cash	$43.0M
Enterprise value	-$9.2M
Basic shares	91.9M shares
Fully diluted shares	103.6M shares
Fully diluted market cap	$38.3M
Cash per share	$0.47

Cash figures as of 2026-06-30. Database snapshot: 2026-09-21.

Price history

Loading CNTX daily closes…

Loading price history…

Upcoming catalysts

Expected	Drug	Phase	Indication	Mgmt guide
Jan 12 - Feb 23	CT-95	Phase 1	Mesothelin-Expressing Tumors; Epithelial Ovarian Cancer; Malignant Pleural Mesothelioma, Advanced	—
Jul 12 - Aug 23	CTIM-76	Phase 1	Platinum-resistant Ovarian Cancer; Testicular Cancer; Endometrial Cancer	—
Feb 12 - Mar 26	CT-202	Phase 1	Triple Negative Breast Cancer (TNBC); Colorectal Cancer; Urothelial Cancer	—

Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.

Full readout calendar →

Pipeline assets

CTIM-76

Phase 1 · Active Modality: bispecific antibody (T cell engager)

Target Claudin 6 (CLDN6) x CD3

Partnerships Integral Molecular: collaboration and licensing agreement for CLDN6 bispecific antibodies (amended Feb 2024; up to $15M development/regulatory milestones, up to $12.5M sales milestones, flat 6% royalty on net sales no sooner than Feb 1, 2034); Lonza: non-exclusive manufacturing license (royalties up to low single digits plus annual payments up to <$500K per asset)

Indications

CLDN6-positive gynecologic and testicular cancers (Phase 1)
Platinum-resistant ovarian cancer (Phase 1)

Catalysts

— second quarter of 2027
— first quarter of 2027

Status note First patient dosed January 2025; interim Phase 1a data presented June 2026. FDA granted Fast Track designation April 2, 2026 for platinum-resistant ovarian cancer in patients who received all standard of care therapies.

CT-202

Phase 1 · Active Modality: bispecific antibody (T cell engager)

Aliases formerly BA3362

Target Nectin-4 x CD3

Partnerships BioAtla: exclusive worldwide license to BioAtla Assets incl. BA3362 ($11M upfront; May 2026 amendment: $4.5M + $2M paid, license now irrevocable, royalty-free, fully paid-up; no future milestones or royalties owed); Lonza: non-exclusive manufacturing license (royalties up to low single digits plus annual payments up to <$500K per asset)

Indications

Nectin-4-positive urothelial, colorectal, and triple-negative breast cancers (Phase 1)

Catalysts

— third quarter of 2026
— second half of 2027

Status note First-in-human Phase 1 cleared in Australia (April 2026 HREC approval/CTN acknowledgement); first patient expected dosed Q3 2026.

CT-95

Phase 1 · Terminated Modality: bispecific antibody (T cell engager)

Target Mesothelin (MSLN) x CD3

Partnerships Link: asset purchase of CT-95-related patent rights, know-how, regulatory filings and drug inventory

Indications

MSLN-positive solid tumors (high grade serous ovarian, pancreatic, mesothelioma) (Phase 1)

Status note Internal development discontinued August 5, 2026 under portfolio prioritization and capital allocation strategy; Phase 1 trial (first patient dosed April 2025) being wound down.

Per-asset detail extracted from the 10-Q filed 2026-08-05. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.

Pipeline

Lead drug	CT-95
Lead indication	Mesothelin-Expressing Tumors
Lead phase	Phase 1
Active trials	3

Active clinical trials

Trial	Phase	Status	Role	Sponsor	BP	Condition(s)	Mgmt guide
NCT06756035	Phase 1	Recruiting	Sponsor	CNTX	—	Mesothelin-Expressing Tumors; Epithelial Ovarian Cancer; Malignant Pleural Mesothelioma, Advanced	—
NCT06515613	Phase 1	Recruiting	Sponsor	CNTX	—	Platinum-resistant Ovarian Cancer; Testicular Cancer; Endometrial Cancer	—
NCT07545122	Phase 1	Recruiting	Sponsor	CNTX	—	Triple Negative Breast Cancer (TNBC); Colorectal Cancer; Urothelial Cancer	—

Sponsor-matched active trials from ClinicalTrials.gov (3 as sponsor, 0 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.

View all 3 active trials for Context Therapeutics Inc. on ClinicalTrials.gov

Institutional holders

Fund	Shares	Q/Q change	% of portfolio	Filing
ADAR1 Capital Management	750,969	+399,875	0.02%	2026-08-14

Institutional holder positions from 13F filings. Q/Q change is vs the prior quarter's filing; % of portfolio is the fund's own reported portfolio weight.

CNTX — Context Therapeutics Inc.

Balance sheet

Price history

Upcoming catalysts

Pipeline assets

Pipeline

Active clinical trials

Institutional holders